Insider Selling: Sana Biotechnology, Inc. (NASDAQ:SANA) Director Sells $612,000.00 in Stock

Sana Biotechnology, Inc. (NASDAQ:SANA) Director Richard Mulligan sold 150,000 shares of the stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $4.28 on Friday. The company has a 50 day simple moving average of $5.17 and a 200 day simple moving average of $6.85. The firm has a market cap of $952.17 million, a PE ratio of -2.80 and a beta of 1.45. Sana Biotechnology, Inc. has a 1 year low of $2.74 and a 1 year high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). As a group, research analysts anticipate that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds have recently made changes to their positions in SANA. ProShare Advisors LLC increased its position in shares of Sana Biotechnology by 14.8% during the first quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock worth $327,000 after buying an additional 4,210 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sana Biotechnology by 20.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after buying an additional 5,090 shares in the last quarter. Swiss National Bank lifted its position in shares of Sana Biotechnology by 3.5% during the 4th quarter. Swiss National Bank now owns 194,100 shares of the company’s stock valued at $792,000 after acquiring an additional 6,600 shares during the period. Arizona State Retirement System boosted its stake in Sana Biotechnology by 36.7% during the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after acquiring an additional 9,940 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Sana Biotechnology in the 2nd quarter valued at about $73,000. 88.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Citigroup raised their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a report on Wednesday, June 26th. They set a “buy” rating and a $16.00 price target on the stock. Finally, HC Wainwright lowered their price target on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, August 9th.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.